Original Article

You have full text access to this OnlineOpen article

K-ras mutation in tamoxifen-related endometrial polyps

  1. Toru Hachisuga M.D.†,*,
  2. Takashi Miyakawa M.D.,
  3. Hiroshi Tsujioka M.D.,
  4. Shinji Horiuchi M.D.,
  5. Makoto Emoto M.D.,
  6. Tatsuhiko Kawarabayashi M.D.

Article first published online: 22 SEP 2003

DOI: 10.1002/cncr.11728

Issue

Cancer

Cancer

Volume 98, Issue 9, pages 1890–1897, 1 November 2003

Additional Information

How to Cite

Hachisuga, T., Miyakawa, T., Tsujioka, H., Horiuchi, S., Emoto, M. and Kawarabayashi, T. (2003), K-ras mutation in tamoxifen-related endometrial polyps. Cancer, 98: 1890–1897. doi: 10.1002/cncr.11728

Author Information

  1. Department of Obstetrics and Gynecology, School of Medicine, Fukuoka University, Fukuoka, Japan

  1. †

    Fax: (011) 81 92 865 4114

*Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, 45-1, 7-chome, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

Publication History

  1. Issue published online: 22 OCT 2003
  2. Article first published online: 22 SEP 2003
  3. Manuscript Accepted: 24 JUL 2003
  4. Manuscript Revised: 14 JUL 2003
  5. Manuscript Received: 10 APR 2003

Funded by

  • Ministry of Education, Science and Culture, Japan. Grant Number: 11671663

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (343K)

REFERENCES

  • 1
    Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer. 1996; 32: 1464–1476.
  • 2
    Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989; 1: 117–120.
  • 3
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527–537.
  • 4
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 1995; 87: 645–651.
  • 5
    Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet. 2000; 36: 881–887.
  • 6
    Deligdisch L, Kalir T, Cohen CJ, Latour MD, Bouedec GL, Llorca FP. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000; 78: 181–196.
  • 7
    Schwartz LB, Krey L, Demopoulos R, Goldstein SR, Nachtigall LE, Mittal K. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol. 1997; 176: 129–137.
  • 8
    Hachisuga T, Hideshima T, Kawarabayashi T, Eguchi F, Emoto M, Shirakusa T. Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium. Int J Gynecol Pathol. 1999; 18: 297–303.
  • 9
    Mourits MJ, Hoor KA, Zee AG, Willemse PH, Vries EG. The effect of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol. 2002; 55: 514–519.
  • 10
    Silva EG, Tornos CS, Mitchell MF. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994; 13: 248–258.
  • 11
    Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994; 47: 827–833.
  • 12
    Weihua Z, Saji S, Makinen S, et al. Estrogen receptor (ER) beta, a modulator of ER alpha in the uterus. Proc Natl Acad Sci U S A. 2000; 97: 5936–5941.
  • 13
    Lecce G, Meduri G, Ancelin M, Bergeron C, Applanat MP. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab. 2001; 86: 1379–1386.
  • 14
    Paech K, Webb P, Kuiper GJ, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science. 1997; 277: 1508–1510.
  • 15
    Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270: 1491–1494.
  • 16
    Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene. 2002; 21; 4921–4931.
  • 17
    Wang Z, Kyo S, Maida Y, et al. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene. 2002; 21: 3517–3524.
  • 18
    Terashima I, Suzuki N, Shibutani S. Mutagenic potential of alpha-(N2-deoxyguanosinyl) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 1999; 59: 2091–2095.
  • 19
    Feng Z, Hu W, Chen JX, et al. Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst. 2002; 94: 1527–1536.
  • 20
    Li D, Firozi PF, Zhang W, et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res. 2002; 513: 37–48.
  • 21
    Sun H, Enomoto T, Shroyer KR, et al. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn Mol Pathol. 2002; 11: 204–211.
  • 22
    Sasaki H, Nishii H, Takahashi H, et al. Mutation of Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993; 53: 1906–1910.
  • 23
    Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mol Pathol. 1999; 52: 257–262.
  • 24
    Lagarda H, Catasus L, Arguelles R, Guiu XM, Prat J. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol. 2001; 193: 193–199.
    Direct Link:
  • 25
    Lax SF, Kendall B, Tashiro H, Siebos RJ, Ellenson LH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Evidence of distinct molecular genetic pathways. Cancer. 2000; 88: 814–824.
    Direct Link:
  • 26
    Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat. 1993; 2: 112–117.
    Direct Link:
  • 27
    Wu DY, Ugozzoli L, Pal BK, Wallace B. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci U S A. 1989; 86: 2757–2760.
  • 28
    Matsubayashi H, Watanabe H, Yamaguchi T, et al. Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma. Jpn J Cancer Res. 1999; 90: 841–848.
  • 29
    Levi S, Ispizua UA, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 1991; 51: 3497–3502.
  • 30
    Mote PA, Balleine PL, McGowan EM, Clarke CL. Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum Reprod. 2000; 15 Suppl 3: 48–56.
  • 31
    Kim K, Lindstrom MJ, Gould MN. Regions of H- and K-ras that provide organ specificity/potency in mammary cancer induction. Cancer Res. 2002; 62: 1241–1245.
  • 32
    Davies R, Oreffo VI, Martin EA, et al. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res. 1997; 57: 1288–1293.
  • 33
    McLuckie KI, Routledge MN, Brown K, et al. DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by alpha-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry. 2002; 41: 8899–8906.
  • 34
    Esteller M, Toyota M, Cespedes MS, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000; 60: 2368–2371.
View Full Article (HTML) Get PDF (343K)